Urica

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, May 15, 2023

MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • In March 2023, the FDA accepted the BLA filing for cosibelimab and set a PDUFA goal date of January 3, 2024.
  • Journey Medical’s total product net revenues were $12.2 million for the first quarter of 2023, compared to first quarter 2022 total product net revenues of $20.8 million.
  • On a non-GAAP basis, Fortress research and development expenses were $2.3 million for the first quarter of 2023, compared to $2.8 million for first quarter of 2022.
  • On a non-GAAP basis, Fortress selling, general and administrative expenses were $7.0 million, for the first quarter of 2023, compared to $6.2 million for the first quarter of 2022.

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023

Fortress has also established 25 acquisition companies with expert opinion leaders in multiple therapeutic areas over the past year.

Key Points: 
  • Fortress has also established 25 acquisition companies with expert opinion leaders in multiple therapeutic areas over the past year.
  • In June 2022, we announced that the topline results of Checkpoint’s pivotal trial of cosibelimab in metastatic cSCC were presented at the 2022 American Society of Clinical Oncology Annual Meeting.
  • Also in June 2022, we announced positive interim results from Checkpoint’s pivotal trial of cosibelimab in locally advanced cSCC.
  • In July 2022, we announced that David Jin, who has served as Vice President of Corporate Development since May 2020, was also appointed as Chief Financial Officer effective August 16, 2022.

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

Retrieved on: 
Wednesday, December 14, 2022

The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.

Key Points: 
  • The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.
  • Under the terms of the agreement, the Company acquired exclusive development and marketing rights in MENA and Turkey from Fuji.
  • In May 2021, Fortress announced an exclusive license agreement between its subsidiary, Urica Therapeutics, Inc. (formerly UR-1 Therapeutics, Inc.), and Fuji Yakuhin Co. Ltd. to develop dotinurad in North America and Europe.
  • In November 2022, Urica licensed rights to dotinurad from Fuji for additional territories including MENA and Turkey.